|
1
|
De Caluwé L, Van Nieuwenhove Y and Ceelen
WP: Preoperative chemoradiation versus radiation alone for stage II
and III resectable rectal cancer. Cochrane Database Syst Rev.
28:22013.
|
|
2
|
Marijnen CA, van de Velde CJ, Putter H,
van den Brink M, Maas CP, Martijn H, Rutten HJ, Wiggers T,
Kranenbark EK, Leer JW and Stiggelbout AM: Impact of short-term
preoperative radio-therapy on health-related quality of life and
sexual functioning in primary rectal cancer: Report of a
multicenter randomized trial. J Clin Oncol. 23:1847–1858. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Camma C, Giunta M, Fiorica F, Pagliaro L,
Craxì A and Cottone M: Preoperative radiotherapy for resectable
rectal cancer: A meta-analysis. J Am Med Assoc. 284:1008–1015.
2000. View Article : Google Scholar
|
|
4
|
Holm T, Rutqvist LE, Johansson H and
Cedermark B: Postoperative mortality in rectal cancer treated with
or without preoperative radiotherapy: Causes and risk factors. Br J
Surg. 83:964–968. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Japanese Society for Cancer of the Colon
Rectum, . Japanese Classification of Colorectal Carcinoma (8th
edition). Kanehara Shuppan. Tokyo: 2013.
|
|
6
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplantat. 48:452–458. 2013. View Article : Google Scholar
|
|
7
|
Frykholm GJ, Glimelius B and Pahlman L:
Preoperative or postoperative irradiation in adenocarcinoma of the
rectum: Final treatment results of a randomized trial and an
evaluation of late secondary effects. Dis Colon Rectum. 36:864–872.
1993. View Article : Google Scholar
|
|
8
|
Peeters KC, Marijnen CA, Nagtegaal ID,
Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius
B, Leer JW, et al: The TME trial after a median follow-up of 6
years: Increased local control but no survival benefit in
irradiated patients with resectable rectal carcinoma. Ann Surg.
246:693–701. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Swedish Rectal Cancer Trial, . Cedermark
B, Dahlberg M, Glimelius B, Påhlman L, Rutqvist LE and Wilking N:
Improved survival with preoperative radiotherapy in resectable
rectal cancer. N Engl J Med. 336:980–987. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bosset JF, Calais G, Mineur L, Maingon P,
Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A and
Collette L: Enhanced tumorocidal effect of chemotherapy with
preoperative radiotherapy for rectal cancer: Preliminary
results-EORTC 22921. J Clin Oncol. 23:5620–5627. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakafusa Y, Hirohashi Y, Tanaka T,
Kitajima Y, Sato S and Miyazaki K: Lateral lymph node dissection in
treatment for advanced lower rectal cancer. Jpn J Gastroenterol
Surg. 34:1512–1521. 2001. View Article : Google Scholar
|
|
12
|
Ishii Y, Hasegawa H, Endo T, Okabayashi K,
Ochiai H, Moritani K, Watanabe M and Kitagawa Y: Medium-term
results of neoadjuvant systemic chemotherapy using irinotecan,
5-fluorouracil, and leucovorin in patients with locally advanced
rectal cancer. Eur J Surg Oncol. 36:1061–1065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hasegawa J, Nishimura J, Mizushima T,
Miyake Y, Kim HM, Takemoto H, Tamagawa H, Noura S, Fujii M, Fujie
Y, et al: Neoadjuvant capecitabine and oxaliplatin (XELOX) combined
with bevacizumab for high-risk localized rectal cancer. Cancer
Chemother Pharmacol. 73:1079–1087. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schrag D, Weiser MR, Goodman KA, Gonen M,
Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem
JG, et al: Neoadjuvant chemotherapy without routine use of
radiation therapy for patients with locally advanced rectal cancer:
A pilot trial. J Clin Oncol. 32:513–518. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kamiya T, Uehara K, Nakayama G, Ishigure
K, Kobayashi S, Hiramatsu K, Nakayama H, Yamashita K, Sakamoto E,
Tojima Y, et al: Early results of multicenter phase II trial of
perioperative oxaliplatin and capecitabine without radiotherapy for
high-risk rectal cancer: CORONA I study. Eur J Surg Oncol.
42:829–835. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hasegawa S, Goto S, Matsumoto T, Hida K,
Kawada K, Matsusue R, Yamaguchi T, Nishitai R, Manaka D, Kato S, et
al: A multicenter phase 2 study on the feasibility and efficacy of
neoadjuvant chemotherapy without radiotherapy for locally advanced
rectal cancer. Ann Surg Oncol. 24:3587–3595. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rödel C, Grabenbauer GG, Papadopoulos T,
Hohenberger W, Schmoll HJ and Sauer R: Phase I/II trial of
capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin
Oncol. 21:3098–3104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tulchinsky H, Shmueli E, Figer A, Klausner
JM and Rabau M: An interval >7 weeks between neoadjuvant therapy
and surgery improves pathologic complete response and disease-free
survival in patients with locally advanced rectal cancer. Ann Surg
Oncol. 15:2661–2667. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roh MS, Colangelo LH, O'Connell MJ,
Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L,
Ursiny CS, Petrelli NJ and Wolmark N: Preoperative multimodality
therapy improves disease-free survival in patients with carcinoma
of the rectum: NSABP R-03. J Clin Oncol. 27:5124–5130. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakuyama N, Kojima M, Kawano S, Akimoto T,
Saito N, Ito M and Ochiai A: Histological differences between
preoperative chemoradiotherapy and chemotherapy for rectal cancer:
A clinicopathological study. Pathol Int. 66:273–280. 2016.
View Article : Google Scholar : PubMed/NCBI
|
